Skip to main content

Advertisement

Table 2 Mean visual acuity in the triple combination therapy with zeaxanthin, triple combination therapy without zeaxanthin and control cohorts

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Year Triple combination therapy with zeaxanthin cohort Triple combination therapy cohort External control cohort (Shah and DelPriore)
1 20/200 20/250 20/200
2 20/160 + 2 20/200 + 1 20/250 − 2
3 20/160 + 2 20/200 + 1 20/320 − 2
4 20/160 + 2 20/200 + 1 20/400 − 1
5 20/160 + 2 20/200 + 1 20/500 + 1
6 20/160 + 2 20/200 + 1 20/500 − 1
7 20/160 + 2 20/200 + 1 20/500 − 2
8 20/160 + 2 20/200 + 1 20/500 − 2
9 20/160 + 2 20/200 + 1 20/640 + 1